Cargando…

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance

In this study we investigated the regulation of FOXM1 expression by estrogen receptor α (ERα) and its role in hormonal therapy and endocrine resistance. FOXM1 protein and mRNA expression was regulated by ER-ligands, including estrogen, tamoxifen (OHT), and fulvestrant (ICI182780; ICI) in breast carc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millour, Julie, Constantinidou, Demetra, Stavropoulou, Alexandra V., Wilson, Miranda S. C., Myatt, Stephen S., Kwok, Jimmy M.-M., Sivanandan, Kavitta, Coombes, R. Charles, Medema, René H., Hartman, Johan, Lykkesfeldt, Anne E., Lam, Eric W.-F.
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874720/ https://www.ncbi.nlm.nih.gov/pubmed/20208560 http://dx.doi.org/10.1038/onc.2010.47

Ejemplares similares

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
por: Millour, J, et al.
Publicado: (2010)

FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c
por: Lam, Andy K. Y., et al.
Publicado: (2013)

Novel functions of FoxM1: from molecular mechanisms to cancer therapy
por: Alvarez-Fernández, Mónica, et al.
Publicado: (2013)

SUMOylation inhibits FOXM1 activity and delays mitotic transition
por: Myatt, S S, et al.
Publicado: (2014)

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance
por: Khongkow, Pasarat, et al.
Publicado: (2013)

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance
por: Khongkow, P, et al.
Publicado: (2016)

Has Hawking erred?
por: Kraus, G
Publicado: (1993)

OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance
por: Karunarathna, U, et al.
Publicado: (2016)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment
por: Kongsema, M, et al.
Publicado: (2016)

FoxM1 repression during human aging leads to mitotic decline and aneuploidy-driven full senescence
por: Macedo, Joana Catarina, et al.
Publicado: (2018)

Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence
por: Littler, D. R., et al.
Publicado: (2010)

Endoplasmic Reticulum (ER) Stress and Endocrine Disorders
por: Ariyasu, Daisuke, et al.
Publicado: (2017)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling
por: Pham, Thu Ha, et al.
Publicado: (2021)

ECM1 is associated with endocrine resistance in ER(+) breast cancers
por: Lee, Tae Won, et al.
Publicado: (2022)

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
por: Maekawa, Akira, et al.
Publicado: (2016)

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER(+) Breast Cancer
por: Ros, Susana, et al.
Publicado: (2020)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis
por: Bergamaschi, Anna, et al.
Publicado: (2011)

The interaction between ER and NFκB in resistance to endocrine therapy
por: Sas, Leen, et al.
Publicado: (2012)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells
por: Alao, John P, et al.
Publicado: (2006)

FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance
por: Intuyod, Kitti, et al.
Publicado: (2018)

TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines
por: Tame, Mihoko A., et al.
Publicado: (2017)

Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy
por: Kim, Tae-Jung, et al.
Publicado: (2012)

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3
por: Zhang, Zhenwang, et al.
Publicado: (2019)

The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells
por: Bergamaschi, Anna, et al.
Publicado: (2014)

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
por: Perone, Ylenia, et al.
Publicado: (2019)

Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma
por: Ito, Takamichi, et al.
Publicado: (2016)

FoxM1 is Upregulated in Osteosarcoma and Inhibition of FoxM1 Decreases Osteosarcoma Cell Proliferation, Migration, and Invasion
por: Zhu, Xia, et al.
Publicado: (2020)

FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients
por: Klinhom-on, Nathakan, et al.
Publicado: (2021)

ANGPTL8 has both endocrine and autocrine effects on substrate utilization
por: Oldoni, Federico, et al.
Publicado: (2020)

ER-positive breast cancer cells are poised for RET-mediated endocrine resistance
por: Horibata, Sachi, et al.
Publicado: (2018)

Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer
por: Jehanno, Charly, et al.
Publicado: (2022)

Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2023)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

Novel Nuclear Partnering Role of EPS8 With FOXM1 in Regulating Cell Proliferation
por: Ngan, Adaline Wan Ling, et al.
Publicado: (2019)

CK1δ modulates the transcriptional activity of ERα via AIB1 in an estrogen-dependent manner and regulates ERα–AIB1 interactions
por: Giamas, Georgios, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oabrbcnkdu14t7bhlhvjt8tsrs